Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).
1 finding from 1 review
Treatment failure · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events: hypertension with seizures · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
1 finding from 1 review
Change in muscle strength ‐ QMT leg score (lb) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Muscle strength · patients with Duchenne muscular dystrophy
2 findings from 1 review
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Body‐mass index (BMI) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes · patients with Duchenne muscular dystrophy
1 finding from 1 review
Fractures ‐ not reported · patients with Duchenne muscular dystrophy
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes · patients with Duchenne muscular dystrophy
It is very uncertain whether deflazacort changes behavioural changes compared with prednisone (very low certainty).
1 finding from 1 review
Fracture · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found